You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Safety of propranolol for infantile hemangioma in infants less than five weeks corrected age
Contributor:
Gatts, Jorie E.;
Rush, Marie C.;
Check, Jennifer F.;
Samelak, Diane M.;
McLean, Thomas W.
Published:
Wiley, 2022
Published in:
Pediatric Dermatology, 39 (2022) 3, Seite 389-393
Language:
English
DOI:
10.1111/pde.14966
ISSN:
0736-8046;
1525-1470
Origination:
Footnote:
Description:
AbstractBackground/ObjectivesPropranolol is used to treat problematic infantile hemangiomas (IHs), but its safety in infants <5 weeks corrected age has not been established. The objective of this study was to assess the safety and efficacy of propranolol for treatment of IH in infants <5 weeks corrected age, or 45 weeks corrected gestational age (CGA).MethodsWe performed a single institution, retrospective review of patients treated with propranolol prior to the age of 6 months between 2017 and 2021. Patient characteristics, location of hemangioma(s), weight at initiation of treatment, dosing information, side effects, response, and duration of treatment were documented.ResultsOf 200 patients with IH treated with propranolol, 24 started treatment prior to 45 weeks CGA. Mean CGA at initiation of treatment was 42 weeks. Sixty‐seven percent were female and 75% were white, non‐Hispanic. Mean duration of treatment was 255 days. Twenty‐two patients (92%) had clear benefit from treatment at a dose of 1–3 mg/kg/day. The most common side effects were sleep disturbance (21%), irritability (17%), and cool hands/feet (13%). There were no serious adverse events.ConclusionsIn this cohort of 24 patients with corrected age <5 weeks (CGA <45 weeks), propranolol was safe and effective for the treatment of infantile hemangiomas. Larger, prospective studies are indicated to investigate propranolol in this age group.